经扣除配售事项佣金及配售事项的其他相关成本及开支后，公司自配售事项收取的所得款项净额约为 3.451亿港元，公司拟将配售事项所得款项净额应用于以下用途：(i)约40%将用于为在中国进行 IMM2510及IMM27M的单一疗法及联合疗法的研发提供资金以治疗实体瘤；(ii)约20%将用于为 IMM01(替达派西普)的研发提供资金；(iii)约10%将用于为IMM0306的研发提供资金；及(iv)约30%将用 于补充公司营运资金，并作一般企业用途。 根据配售协议的条款及条件，配售代理已按每股配售股份14.50港元的配售价成功向不少于六名承配人 配售合共2420万股配售股份，占紧接交割前公司已发行股本数目约5.94%及已发行H股总数约6.11%，以 及占紧随交割後经配发及发行配售股份扩大后的公司已发行股本数目约5.61%及已发行H股总数约 5.76%。 格隆汇10月16日丨宜明昂科-B(01541.HK)宣布，配售协议所载的所有先决条件已达成且交割已根据配售 协议的条款及条件于2025年10月16日落实。 ...

公司股价周四低开，至中午休市报14.46港元，跌13.21%。不过今年以来公司股价仍升180%。 创新药企业宜明昂科（1541.HK）周四宣布，拟配售2,420万股新H股，约占扩大后股本约5.61%，集资 3.51亿港元（4,500万美元），每股配售价14.5港元，较前一日收市价格16.66港元折让约12.97%。 来源：市场资讯 公司表示，所得款项净额估计达约3.45亿元，将用于为在中国进行IMM2510及IMM27M的单一疗法及联 合疗法的研发提供资金以治疗实体瘤；为IMM01(替达派西普)的研发提供资金，以及为IMM0306的研发 提供资金，补充营运资金与一般企业用途。 （来源：BBW咏竹坊） 宜明昂科日前已向国家药品监督管理局药品审评中心，提交IMM2510用于治疗经免疫治疗耐药性非小 细胞肺癌（NSCLC）的三期临床试验的申请。 ...

宜明昂科-B(01541)发布公告，于2025年10月9日，公司拟配售合共2420万股新H股，占公司经配发及发 行配售股份扩大后已发行股本约5.61%。每股配售股份14.50港元的配售价，较10月8日收市价每股16.66 港元折让约12.97%。 公司自配售事项收取的所得款项总额及所得款项净额估计分别为约3.509亿港元及约3.45亿港元。公司拟 将配售事项所得款项净额应用于以下用途：(i)约40%将用于为在中国进行IMM2510及IMM27M的单一疗 法及联合疗法的研发提供资金以治疗实体瘤;(ii)约20%将用于为IMM01(替达派西普)的研发提供资金;(iii) 约10%将用于为IMM0306的研发提供资金;(iv)约30%将用于补充公司营运资金，并作一般企业用途。 ...

公司自配售事项收取的所得款项总额及所得款项净额估计分别为约3.509亿港元及约3.45亿港元。公司拟 将配售事项所得款项净额应用于以下用途：(i)约40%将用于为在中国进行IMM2510及IMM27M的单一疗 法及联合疗法的研发提供资金以治疗实体瘤;(ii)约20%将用于为IMM01(替达派西普)的研发提供资金;(iii) 约10%将用于为IMM0306的研发提供资金;(iv)约30%将用于补充公司营运资金，并作一般企业用途。 智通财经APP讯，宜明昂科-B(01541)发布公告，于2025年10月9日，公司拟配售合共2420万股新H股， 占公司经配发及发行配售股份扩大后已发行股本约5.61%。每股配售股份14.50港元的配售价，较10月8 日收市价每股16.66港元折让约12.97%。 ...

公司自配售事项收取的所得款项总额及所得款项净额估计分别为约3.509亿港元及约3.451亿港元。公司 拟将配售事项所得款项净额应用于以下用途：约40%将用于为在中国进行IMM2510及IMM27M的单一疗 法及联合疗法的研发提供资金以治疗实体瘤；约20%将用于为IMM01(替达派西普)的研发提供资金；约 10%将用于为IMM0306的研发提供资金；及约30%将用于补充公司营运资金，并作一般企业用途。 格隆汇10月9日丨宜明昂科-B(01541.HK)发布公告，2025年10月9日(交易时段前)，公司与配售代理(即瑞 银集团)订立配售协议，据此，配售代理已同意担任公司的独家配售代理，尽力促使认购人按配售协议 所载条款及在受该协议所载条件的规限下以每股配售股份14.50港元的配售价认购合共2420万股新H股。 每股配售股份14.50港元的配售价较H股于最后交易日在联交所所报收市价每股16.66港元折让约 12.97%。配售股份分别占公司于本公告日期的已发行股本及已发行H股总数约5.94%及约6.11%。配售股 份将根据一般授权配发及发行。 ...

Company Overview - Yiming Biopharmaceutical Technology (01541.HK) was established in 2015 and listed on the Hong Kong main board in September 2023, focusing on "immune system activation" to develop innovative drugs that help the body's immune cells attack cancer cells [2] - Key products include IMM01 (activates the immune system to engulf cancer cells) and IMM2510 (a globally pioneering bispecific antibody drug that simultaneously inhibits tumor angiogenesis and activates immunity) [2] Product Pipeline - Currently, there are 6 products in Phase III clinical trials [3] Management and Shareholders - The founder and Chief Scientific Officer, Dr. Tian Wenzhi, holds approximately 17% of the shares and has over 30 years of experience in the biopharmaceutical industry, overseeing the company's overall strategy and clinical progression [5] - Major shareholders include Shanghai Zhangke Leading Investment (approximately 9%) and LAV Asset Management (approximately 6.8%), both of which have a strong focus on early-stage biopharmaceutical investments [6] Financial Performance - The company reported revenues of RMB 538,000 in 2022, with a net loss of RMB 402.894 million, and in 2023, revenues decreased to RMB 386,000 with a net loss of RMB 379.459 million [8][9] - In 2024, revenues are projected to increase significantly to RMB 74.149 million, driven by a licensing agreement with Axion Bio, which contributed approximately RMB 71.342 million [11] - The company has maintained high R&D investment, with expenditures of RMB 320 million in 2024, which is 4.4 times its revenue [11] Product Advantages - IMM2510 employs a dual-pathway immune strategy, combining innate and adaptive immunity, and has completed Phase I dose exploration with promising early data [16] - IMM0306, a CD47×CD20 bispecific fusion protein, has a high effective relief rate of 91%, outperforming competitors [17] Industry Trends - The global immuno-oncology market is expected to grow from approximately USD 126.5 billion in 2024 to about USD 271.1 billion by 2033, with a CAGR of 8.6% to 10.65% [18] - The market is driven by rising cancer incidence rates, with an estimated 20 million new cases in 2022, projected to increase to 35 million by 2050 [18] Competitive Landscape - The company avoids the highly competitive single-pathway PD-1 market and focuses on combination therapies targeting CD47 and CD20, which may qualify for orphan drug status and expedited approval [21] Valuation and Market Performance - The company's stock price has increased by 178.6% year-to-date, driven by significant R&D progress and market interest in the biopharmaceutical sector [24] - Revenue projections for 2025-2027 are estimated at RMB 201 million, RMB 122 million, and RMB 312 million, respectively, with a target market value of HKD 8.915 billion [24]